GlassScriptPhysician profile
Amy L Hennessy
NPI 1780892836
$2,909.06
in general payments reported to CMS, 2019-2025
15 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $45.00 · 2021: $284 · 2022: $452 · 2023: $627 · 2024: $445 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,239.21 | 2021-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Abbvie INC. | $372.92 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $276.74 | 2019-2021 | |
| Oyster Point Pharma, INC. | $183.02 | 2022-2024 | Tyrvaya |
| Allergan, INC. | $178.71 | 2019-2021 | |
| Dompe US, INC. | $119.86 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $109.95 | 2019 | |
| Glaukos Corporation | $108.52 | 2019-2024 | Idose |
| Ivantis, INC | $96.43 | 2021 | |
| Sight Sciences, INC. | $77.40 | 2023-2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $62.73 | 2022-2023 | Tecnis Iol |
| Astellas Pharma US INC | $33.44 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $18.32 | 2025 | Xdemvy |
| Thea Pharma INC. | $16.01 | 2024 | Iyuzeh |
| Bausch & Lomb Americas INC. | $15.80 | 2025 | Miebo, Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Hennessy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.